Bioverativ (NASDAQ:BIVV) received a $53.00 price objective from equities research analysts at Deutsche Bank in a research report issued to clients and investors on Monday, November 20th. The brokerage presently has a “hold” rating on the biotechnology company’s stock. Deutsche Bank’s price objective indicates a potential upside of 4.58% from the company’s previous close.
Several other equities analysts also recently commented on BIVV. Zacks Investment Research raised Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 price objective on the stock in a research report on Tuesday, July 25th. Cowen reissued a “buy” rating and set a $80.00 price target on shares of Bioverativ in a research report on Friday, August 4th. Jefferies Group reissued a “buy” rating and set a $70.00 price target (up previously from $67.00) on shares of Bioverativ in a research report on Wednesday, August 9th. Evercore ISI started coverage on Bioverativ in a research report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price target on the stock. Finally, Royal Bank Of Canada started coverage on Bioverativ in a research report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price target on the stock. One analyst has rated the stock with a sell rating, nine have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $60.93.
Shares of Bioverativ (NASDAQ BIVV) traded up $0.43 during trading on Monday, reaching $50.68. The company’s stock had a trading volume of 782,429 shares, compared to its average volume of 1,605,192. Bioverativ has a 12 month low of $40.00 and a 12 month high of $64.41.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.25. The company had revenue of $291.60 million for the quarter, compared to the consensus estimate of $285.45 million. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The company’s revenue for the quarter was up 27.2% compared to the same quarter last year. equities research analysts expect that Bioverativ will post 2.45 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of BIVV. Quotient Investors LLC purchased a new stake in shares of Bioverativ during the 3rd quarter worth $420,000. Mutual of America Capital Management LLC purchased a new stake in shares of Bioverativ during the 3rd quarter worth $5,062,000. Meeder Asset Management Inc. purchased a new stake in shares of Bioverativ during the 3rd quarter worth $877,000. Rockefeller Financial Services Inc. purchased a new stake in shares of Bioverativ during the 3rd quarter worth $1,480,000. Finally, State Treasurer State of Michigan purchased a new stake in shares of Bioverativ during the 3rd quarter worth $2,323,000. Hedge funds and other institutional investors own 95.23% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Deutsche Bank Analysts Give Bioverativ (BIVV) a $53.00 Price Target” was first published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://ledgergazette.com/2017/12/07/bioverativ-inc-bivv-given-a-53-00-price-target-by-deutsche-bank-ag-analysts.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.